I said the good news is priced in. Many drugs fail their first attempt to gain FDA approval - usually having to make minor adjustments (say marketing, pricing, clarification of data, etc).
As such, there is more downside risk at the moment - for example, if it fails on its first attempt it falls 40%. If it is approved then it jumps 10% to 15%.
The drug will eventually get approved - but I'm not risking a potential 10% gain for a -40% drop.
CXS Price at posting:
86.0¢ Sentiment: ST Sell Disclosure: Not Held